NASDAQ:JUNS Jupiter Neurosciences Q4 2024 Earnings Results & Report $2.85 +0.08 (+2.89%) Closing price 10/9/2026 03:59 PM EasternExtended Trading$2.87 +0.02 (+0.67%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Jupiter Neurosciences missed analyst earnings expectations in its Q4 2024 results, released March 28, 2025. The company reported EPS of -$3.75 versus the -$1.50 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 28, 2025TimeAfter Market Closes Jupiter Neurosciences EPS ResultsActual EPS-$3.75Consensus EPS -$1.50Beat/MissMissed by -$2.25One Year Ago EPSN/AEPS Beat Rate1 of last 6 quartersJupiter Neurosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsJupiter Neurosciences' next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Jupiter Neurosciences Q4 2024 Earnings FAQ Did Jupiter Neurosciences beat earnings estimates for Q4 2024? Jupiter Neurosciences (NASDAQ:JUNS) reported earnings of -$3.75 per share for Q4 2024, missing the consensus estimate of -$1.50. The report was announced on Friday, March 28, 2025. When is Jupiter Neurosciences' next earnings date? Jupiter Neurosciences' next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Jupiter Neurosciences on the company's earnings history page. Jupiter Neurosciences Earnings HeadlinesJupiter Neurosciences (NASDAQ:JUNS) Stock Jumps 18.2% - Time to Buy?October 7 at 1:41 AM | americanbankingnews.comJupiter Neurosciences Starts Phase 2a Parkinson's Trial Of JOTROLOctober 6, 2026 | rttnews.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 10 at 1:00 AM | Altimetry (Ad)Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder ValueOctober 6, 2026 | markets.businessinsider.comJupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial of JOTROL for Parkinson’s Disease and Reviews Strategic AlternativesOctober 6, 2026 | quiverquant.comQJupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson's Disease and Exploration of Strategic Options to Maximize Shareholder ValueOctober 6, 2026 | globenewswire.comSee More Jupiter Neurosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Jupiter Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jupiter Neurosciences and other key companies, straight to your email. Email Address About Jupiter NeurosciencesJupiter Neurosciences (NASDAQ:JUNS) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders associated with neuroinflammation. The company’s research centers on resveratrol, a naturally occurring compound that has been studied for potential anti-inflammatory and neuroprotective effects. Its primary product candidate is JOTROL™, a proprietary oral formulation designed to improve the delivery and bioavailability of resveratrol. Jupiter Neurosciences is evaluating JOTROL for potential use in conditions including Alzheimer’s disease, Friedreich’s ataxia and other neurological disorders. The company’s programs remain in development, and its product candidates have not been approved for commercial use. Jupiter Neurosciences is based in the United States and is conducting its work through preclinical and clinical development programs. Publicly available information about the company’s broader operations, geographic reach and leadership is limited.View Jupiter Neurosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
